Healthy volunteers needed to donate samples for vaccine research

NCT ID NCT00067054

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 23 times

Summary

This study collects blood, urine, skin swabs, and other samples from healthy volunteers to help researchers at the National Institutes of Health study diseases like HIV and hepatitis, and to develop new vaccines. Participants must be 18 or older and can donate samples one time or repeatedly over a year. The samples are used for laboratory research only, not to treat any specific condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2003

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants may be individuals participating solely in this protocol or may be individuals in other VRC studies from whom more cells are needed for research than can be collected by routine phlebotomy.At the VRC site, NIH employees and members of their immediate families may participate in this protocol. The UPR MSC site will only enroll participants from the community. Children are not eligible to participate in this clinical trial.

Ages

3 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA FOR ADULT PARTICIPANTS: A participant must meet all the inclusion criteria, as follows: 1. Age 18 years or older 2. Able and willing to complete the informed consent process 3. Willing to provide blood or other samples that will be stored indefinitely and used for future research 4. Able to provide proof of identity to the acceptance of the clinician completing the enrollment process; when informed consent is obtained by telephone or a telehealth visit, the investigator obtaining consent will also confirm proof of identity. INCLUSION CRITERIA FOR CHILDREN: 1. Children aged 3 to 17 years inclusive, and at least 12 kg in weight. 2. Capability of the legal adult guardian of the child to understand and comply with the planned study procedures. 3. Capability of the legal adult guardian of the child to provide written informed consent. 4. Willing to have blood drawn or collection of urine, fecal samples, oral secretions, or swabs of mucosa that will be stored indefinitely and used for future research. 5. The legal adult guardian of the children can provide proof of identity for the child and for themselves to the satisfaction of the clinician completing the enrollment process. EXCLUSION CRITERIA FOR ALL PARTICIPANTS: A participant will be excluded from protocol participation if there is presence of a condition that the attending physician considers to be a contraindication to the specimen collection procedures. EXCLUSION CRITERIA FOR CHILDREN ONLY 1. Acute or chronic illness that, in the opinion of the investigator or designee, precludes participation in the study. 2. Factors related to the legal guardian that, in the judgment of the investigator or designee, may affect the objective decision-making of the legal guardian. SKIN BIOPSY ELIGIBILITY CRITERIA FOR ADULTS ONLY: The skin biopsy eligibility includes the following: 1. Age 18 years or older 2. No known allergies to the local anesthetic to be used 3. No history of keloid formation 4. No known coagulation disorders 5. Not pregnant or breast feeding APHERESIS ELIGIBILITY CRITERIA FOR ADULTS ONLY: * To undergo an apheresis procedure, a participant must have no medical contraindications. All apheresis procedures performed under this protocol are solely for research purposes. * Participants involved in an active clinical research protocol may participate in the apheresis protocol if the total amount of blood drawn does not exceed NIH guidelines or a site's institutional guidelines. A study clinician will complete a checklist for apheresis eligibility before referring a participant for apheresis. * At the NIH, prior to the scheduled procedure, the participant must have a venous assessment performed by apheresis staff to determine suitability for apheresis. For Healthy Volunteers: A healthy volunteer must meet all the following criteria prior to the procedure: 1. Age 18 years or older 2. Afebrile (temperature \<= 37.5 degrees C) 3. Weight \>=110 pounds 4. Adequate bilateral antecubital venous access 5. Hemoglobin \>= 12.5 g/dL for women; \>= 13.0 g/dL for men within 56 days prior to apheresis procedure. 6. Platelets \> 150,000 K/uL within 56 days prior to apheresis procedure. 7. No cardiovascular instability as indicated by a) history of medically significant cardiac arrhythmia within the last 12 months, or b) ischemic cardiovascular disease within the last 12 months, or c) heart rate outside of the 50-100 beats/minute interval (on 3 successive readings), or d) blood pressure greater than 180 mmHg (systolic) or 100 mmHg (diastolic) on 3 successive readings 8. No current lung or kidney disease 9. No known coagulation disorder 10. No sickle cell disease 11. No active or chronic hepatitis 12. No intravenous injection drug use in the past 5 years 13. Not breast feeding 14. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) performed by a VRC study clinician within 72 hours prior to the apheresis procedure Patients with an Infectious Disease: A patient with an infectious disease must meet all the following criteria: 1. Age 18 years or older 2. Weight \>= 110 pounds 3. Afebrile (temperature \<= 37.5 degrees C) 4. Adequate bilateral antecubital venous access 5. No cardiovascular instability as indicated by a) history of medically significant cardiac arrhythmia within the last 12 months, or b) ischemic cardiovascular disease within the last 12 months, or c) heart rate outside of the 50-100 beats/minute (on 3 successive readings), or d) blood pressure greater than 180/100 mmHg (on 3 successive readings) 6. No current lung or kidney disease 7. No known coagulation disorder 8. No receipt of clotting factor concentrates in the past 5 years 9. Hemoglobin \>= 9.0 g/dL within 56 days prior to apheresis procedure 10. Platelets \>= 50,000 K/uL within 56 days prior to apheresis procedure 11. White Blood Cell (WBC) \>= 2.0 K/uL within 56 days prior to apheresis procedure 12. Not breast feeding 13. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) performed by a VRC study clinician within 72 hours prior to the apheresis procedure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sample collection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • EvergreenHealth Medical Center

    COMPLETED

    Kirkland, Washington, 98034, United States

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

  • University of Puerto Rico Medical Sciences Campus

    ACTIVE_NOT_RECRUITING

    San Juan, 00921, Puerto Rico